Success Metrics

Clinical Success Rate

100.0%

Based on 1 completed trials

Completion Rate

100%(1/1)

Active Trials

4(80%)

Results Posted

0%(0 trials)

Phase Distribution

Ph phase_1

20%

Ph phase_2

20%

Ph phase_3

60%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution5 total trials

Phase 1Safety & dosage

1(20.0%)

Phase 2Efficacy & side effects

1(20.0%)

Phase 3Large-scale testing

3(60.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(4)

Completed(1)

Detailed Status

Active, not recruiting3

Recruiting1

Completed1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 3

Trials by Phase

Phase 11 (20.0%)

Phase 21 (20.0%)

Phase 33 (60.0%)

Trials by Status

recruiting120%

active_not_recruiting360%

completed120%

Recent Activity

4 active trials

Showing 5 of 5

recruitingphase_3

A Study of MIL62 in Patients With Neuromyelitis Optica Spectrum Disorder (NMOSD)

NCT05314010

active_not_recruitingphase_3

A Phase Ⅲ Clinical Study of MIL62 in Primary Membranous Nephropathy

NCT05862233

Clinical Trials (5)

Showing 5 of 5 trials

NCT07405970Phase 3

A Phase 3 Clinical Study of MIL62 in Systemic Lupus Erythematosus

Recruiting

NCT05796206Phase 2

A Phase 2 Clinical Study of MIL62 in Systemic Lupus Erythematosus

Active Not Recruiting

NCT05398653Phase 1

A Phase Ib/ Ⅱ Clinical Study of MIL62 in Primary Membranous Nephropathy

Completed

NCT05314010Phase 3

A Study of MIL62 in Patients With Neuromyelitis Optica Spectrum Disorder (NMOSD)

Active Not Recruiting

NCT05862233Phase 3

A Phase Ⅲ Clinical Study of MIL62 in Primary Membranous Nephropathy

Active Not Recruiting

All 5 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 5